950 Darbepoetin alfa significantly improved fatigue in patients with lymphoproliferative malignancies undergoing chemotherapy: results of a phase 3 multicenter, randomized, double-blind, placebo-controlled study

H.Michael; J.Kallich; J.San Miguel; D.Watson; J.Matcham; T.J.Littlewood

首页> 外文期刊>European Journal of Cancer Supplements >950 Darbepoetin alfa significantly improved fatigue in patients with lymphoproliferative malignancies undergoing chemotherapy: results of a phase 3 multicenter, randomized, double-blind, placebo-controlled study

【24h】

950 Darbepoetin alfa significantly improved fatigue in patients with lymphoproliferative malignancies undergoing chemotherapy: results of a phase 3 multicenter, randomized, double-blind, placebo-controlled study

机译：950 Darbepoetin alfa显着改善了正在接受化疗的淋巴增生性恶性肿瘤患者的疲劳：一项3期多中心，随机，双盲，安慰剂对照研究的结果

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共2页
作者
H.Michael; J.Kallich; J.San Miguel; D.Watson; J.Matcham; T.J.Littlewood;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 685 A phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa in patients (pts) with lymphoproliferative malignancies [J] . M.Hedenus, J.San Miguel, D.Watson, European Journal of Cancer Supplements . 2003,第5期

机译：685 A第3期，随机，双盲，安慰剂对照研究darbepoetin alfa在淋巴增生性恶性肿瘤患者中的研究
2. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC [J] . Gascon Pere, Nagarkar Rajnish, Smakal Martin, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2020,第2期

机译：随机，双盲，安慰剂控制，III期非易生性研究达到高级NSCLC患者化疗诱导的贫血的长期安全性和功效
3. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. [J] . Smith-RE Jr, Aapro MS, Ludwig H, Journal of Clinical Oncology . 2008,第7期

机译：Darbepoetin alpha用于治疗未接受化学疗法或放射疗法的活动性癌症患者的贫血：III期，多中心，随机，双盲，安慰剂对照研究的结果。
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. A Phase III Randomized Placebo-Controlled Double-Blind Clinical Trial of the Effect of Modafinil on Cancer-Related Fatigue among 631 Patients Receiving Chemotherapy: A URCC CCOP Research Base Study [O] . Pascal Jean-Pierre, Gary R. Morrow, Joseph A. Roscoe, -1

机译：III期随机安慰剂控制双盲临床试验Modafinil对接受化疗的631例患者癌症相关疲劳的影响：URCC CCOP研究基础研究
7. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC [O] . Pere Gascón, Rajnish Nagarkar, Martin Šmakal, 2020

机译：随机，双盲，安慰剂控制，III期非易生性研究达到高级NSCLC患者化疗诱导的贫血的长期安全性和功效

950 Darbepoetin alfa significantly improved fatigue in patients with lymphoproliferative malignancies undergoing chemotherapy: results of a phase 3 multicenter, randomized, double-blind, placebo-controlled study

著录项

相似文献

相关主题

期刊订阅